RFA Using Gradual RF Energy Delivery Mode With Octopus Electrodes
Radiofrequency Ablation for Hepatocellular Carcinoma Using Gradual RF Energy Delivery Mode With Octopus Electrodes: A Prospective Observational Study
1 other identifier
interventional
120
1 country
1
Brief Summary
The investigators intend to perform RFA therapy on HCC less than 4 cm in size using octopus electrode, double alternating unipolar high-frequency transmission mode and gradual high-frequency energy loading mode, and to find out the therapeutic results. The primary evaluation variable is the ideal technical success rate for securing a safety margin of 5 mm or more around the tumor on the CT obtained immediately after the procedure, and the secondary evaluation variable is the volume of the cauterization lesion per unit time measured on the CT obtained immediately after the procedure, The local tumor recurrence rate, survival rate and disease-free survival rate of 12 months after the procedure, the presence or absence of multiple recurrences within the same segment, the actual procedure time, and the incidence of complications associated with the procedure are examined. The performance of RFA therapy of HCC using the Octopus electrode and gradual high-frequency energy transfer mode is compared with that of the existing Octopus electrode and RFA therapy using the basic maximum high-frequency energy transfer mode using historic cohort.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2020
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 6, 2020
CompletedFirst Submitted
Initial submission to the registry
March 31, 2020
CompletedFirst Posted
Study publicly available on registry
July 15, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2023
CompletedMarch 17, 2021
March 1, 2021
2.6 years
March 31, 2020
March 16, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Ideal technical success rate
Secure a safety margin of 5 mm or more around the tumor on CT obtained immediately after the procedure
Time: immediately
Secondary Outcomes (6)
Ablation volume
Time: immediately
Local recurrence rate
Time: 12months
Overall survival rate
Time: 3years
Disease free survival
Time: 3years
Complication rate
Time: immediately
- +1 more secondary outcomes
Study Arms (1)
RFA using gradual RF energy delivery mode
EXPERIMENTALRFA therapy is performed on HCC less than 4 cm in size using an octopus electrode, a double-shift unipolar high-frequency transmission mode, and a gradual high-frequency energy loading mode.
Interventions
RFA therapy is performed on HCC less than 4 cm in size using an octopus electrode, a double-shift unipolar high-frequency transmission mode, and a gradual high-frequency energy loading mode.
Eligibility Criteria
You may qualify if:
- agree to the protocol's requirements and submit a consent form
- years old-85 years old
- Child-Pugh Class A
- among patients with chronic hepatitis or cirrhosis, MDCT or MRI hepatocellular carcinoma of less than 4 cm in size was suspected, and was referred to the radiology department considering clinical RFA therapy as a clinical judgment.
You may not qualify if:
- when the number of malignant HCC is 3 or more
- if the tumor has a maximum size of more than 4 cm
- diffuse infiltrative HCC
- Child-Pugh class B or C
- If there is an invasion of liver vessels due to malignant HCC
- severe coagulopathy
- multiple distant metastasis
- situations where it is very unlikely to obtain appropriate data for research purposes
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Seoul National University Hospital
Seoul, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
March 31, 2020
First Posted
July 15, 2020
Study Start
January 6, 2020
Primary Completion
August 30, 2022
Study Completion
December 30, 2023
Last Updated
March 17, 2021
Record last verified: 2021-03
Data Sharing
- IPD Sharing
- Will not share